New Risk • Jul 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩30.0b market cap, or US$19.6m). 공고 • Mar 17
Epibiotech Co., Ltd., Annual General Meeting, Mar 31, 2026 Epibiotech Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 32, songdogwahak-ro, yeonsu-gu, incheon South Korea New Risk • Sep 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (₩33.0b market cap, or US$23.8m). 공고 • Apr 24
Epibiotech Co., Ltd. announced that it has received KRW 850 million in funding from Korea Investment Partners Co. Ltd. On April 24, 2025 Epibiotech Co., Ltd. closed the transaction. 공고 • Apr 17
Epibiotech Co., Ltd. announced that it expects to receive KRW 850 million in funding Epibiotech Co., Ltd. announced a private placement to issue 53,125 Registered Convertible Preferred Stock due April 24, 2035 at an issue price of KRW 16,000 per share for gross proceeds of KRW 850,000,000 on April 16, 2025. The transaction will include participation from new investor Korea Investment Core Competency Leverage II Fund. The transaction has been approved by shareholders, restricted to a hold period, expected to close on April 24, 2025, 100% convertible into 53,125 shares at a a fixed conversion price of KRW 16,000 from April 24, 2026 to April 23, 2035 and matures on April 24, 2035. 공고 • Mar 20
Epibiotech Co., Ltd. announced that it has received KRW 1.7 billion in funding On March 19, 2025, Epibiotech Co., Ltd. closed the transaction. 공고 • Mar 13
Epibiotech Co., Ltd., Annual General Meeting, Mar 26, 2025 Epibiotech Co., Ltd., Annual General Meeting, Mar 26, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 32, songdogwahak-ro, yeonsu-gu, incheon South Korea 공고 • Mar 12
Epibiotech Co., Ltd. announced that it expects to receive KRW 1.7 billion in funding Epibiotech Co., Ltd. announced a private placement to issue 106,250 Nominal Convertible Preferred Stock at an issue price of KRW 16,000 for gross proceeds of KRW 1,700,000,000 on March 11, 2025. The transaction will include participation from new investor Kikai Bio New Technology Investment Fund No.1. The shares are 100% convertible into 106,250 shares at a fixed conversion price of KRW 16,000 from March 19, 2026 to March 18, 2035 and duration is March 18, 2035 and is expected to close on March 18, 2025 and is restricted to a hold period. New Risk • Nov 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₩24.1b market cap, or US$17.3m). New Risk • Apr 02
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risk Market cap is less than US$100m (₩25.7b market cap, or US$19.0m).